← All FDA warning letters

FDA Warning Letter · #705501

cheaptrustedpharmacy.com: FDA Warning Letter (July 29, 2025)

cheaptrustedpharmacy.com received this warning letter on July 29, 2025, from FDA’s Center for Drug Evaluation and Research (CDER). What it cites, and FDA’s own words where we matched them against the letter, are summarized below.

Issued July 29, 2025Status: activeCenter for Drug Evaluation and Research (CDER)On this register since August 16, 2026
By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Primary Source

View the original FDA letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheaptrustedpharmacycom-705501-07292025

Summary

Company
cheaptrustedpharmacy.com
Letter number
#705501
Issue date
July 29, 2025
Subject
Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet

What FDA cited

FDA's letter of July 29, 2025 cites cheaptrustedpharmacy.com for selling products FDA calls unapproved new drugs, under the subject line "Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet". The GLP-1 drugs it names: semaglutide.

In FDA’s words:
On www.cheaptrustedpharmacy.com you offer for sale injectable semaglutide marketed as “Semaglutide 0.5mg,” “Semaglutide 1mg,” “Semanize 4 Mg (Semaglutide),” and “Semanize 8 Mg (Semaglutide).” … While there are FDA-approved versions of semaglutide on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for the “Semaglutide 0.5mg,” “Semaglutide 1mg,” “Semanize 4Mg (Semaglutide),” and “Semanize 8 Mg (Semaglutide)” offered by www.cheaptrustedpharmacy.com.

How this letter sits against the other 159

Our reading, from the 160 letters on this register — not part of the FDA’s document.

No other letter on this register carries the date July 29, 2025. The agency acted against this company on its own that day, which is uncommon here — most of the letters we hold arrived in sweeps.

A warning letter is the agency putting a company on notice, not a court finding and not a ban. What it is worth to you is in what it alleges, so read the original on fda.gov rather than the fact that one exists.

For checking a pharmacy website before you order: How to verify an online GLP-1 pharmacy: six public checks.

FDA’s letter of September 9, 2025 to Amazing Meds also cites its recipient for selling products FDA calls unapproved new drugs.

What FDA warning letters mean

It is the agency writing to a company to say it believes something that company is doing breaks the Federal Food, Drug, and Cosmetic Act — usually a claim on a website, a labeling choice, or how a drug is being made. The company has about fifteen working days to write back.

Read carefully what it is not. It is not a recall, not a criminal charge, and not a court deciding anyone broke the law. It is the regulator opening a file. Companies frequently answer a letter, fix what was cited, and carry on trading, and when FDA accepts that it can issue a close-out letter. We do not track close-outs, so the presence of a letter on this page tells you what FDA said on one date — not where the matter stands today. Ask the company; they will usually tell you, and how they answer is informative in itself.

Across this market the same three citations recur: claiming a compounded product is equivalent to an approved one, labeling that misleads, and compounding from bulk substances FDA has not cleared under sections 503A and 503B. If you are reading a letter here, it is probably one of those.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.1

Sesame Care

Oral orforglipron alongside the injectables

7.2

Oak

A choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout

8.2

bmiMD

Starting below a standard dose, with microdose tiers

Other warning letters in our database

View the full database →

Editorial Disclaimer

This is a public communication from a regulator, and by itself it settles nothing about whether the company broke any law. Corrective action is a common response, and a fair number of letters end in a close-out. Read the whole thing on fda.gov through the link above rather than taking our excerpt as the full picture.

Glossary

The words sellers use, defined. Tap any term.